Pegfilgrastim-associated large-vessel vasculitis developed during adjuvant chemotherapy for breast cancer: A case report and review of the literature
- 18 March 2020
- journal article
- review article
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
- Vol. 26 (7), 1785-1790
- https://doi.org/10.1177/1078155220910800
Abstract
Granulocyte colony-stimulating factor (G-CSF) is widely used as a neutrophil supportive therapy in breast cancer chemotherapy. Common adverse events of G-CSF include bone pain, headache, and fatigue; however, reports of G-CSF-associated vasculitis are few. A 66-year-old woman who had undergone surgery for breast cancer received adjuvant chemotherapy with prophylactic use of pegfilgrastim (peg-G). She developed peg-G-associated vasculitis 11 days after initially receiving peg-G. Management and outcome: Although various blood and culture tests were required to rule out other vasculitis syndromes and infections, her symptoms spontaneously disappeared without any treatment other than discontinuation of the causal drug. G-CSF-associated vasculitis is occasionally accompanied by severe complications such as aortic dissection and aneurysm formation. This case report is important to draw attention towards this rare and difficult-to-diagnosis adverse event of peg-G.Keywords
This publication has 27 references indexed in Scilit:
- Racial differences in acute toxicities of neoadjuvant or adjuvant chemotherapy in patients with early-stage breast cancerEuropean Journal of Cancer, 2011
- Changes of cytokine levels during granulocyte-colony-stimulating factor stem cell mobilization in healthy donors: association with mobilization efficiency and potential predictive significanceTransfusion, 2010
- Abdominal Aortitis after Use of Granulocyte Colony-Stimulating FactorClinical Drug Investigation, 2009
- Review article: Drug‐induced anti‐neutrophil cytoplasmic antibody‐associated vasculitisNephrology, 2009
- Granulocyte Colony–Stimulating Factor Administration: Adverse EventsTransfusion Medicine Reviews, 2008
- GM-CSF mediates autoimmunity by enhancing IL-6–dependent Th17 cell development and survivalThe Journal of Experimental Medicine, 2008
- Aortite après injections de G-CSFLa Revue de Médecine Interne, 2004
- Spontaneous splenic rupture with fatal outcome following G‐CSF administration for myelodysplastic syndromeAmerican Journal of Hematology, 2003
- Blinded, Randomized, Multicenter Study to Evaluate Single Administration Pegfilgrastim Once per Cycle Versus Daily Filgrastim as an Adjunct to Chemotherapy in Patients With High-Risk Stage II or Stage III/IV Breast CancerJournal of Clinical Oncology, 2002
- Acute arterial thrombosis due to platelet aggregation in a patient receiving granulocyte colony‐stimulating factorBritish Journal of Haematology, 1996